A
Annick D. Van den Abbeele
Researcher at Harvard University
Publications - 132
Citations - 16812
Annick D. Van den Abbeele is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Imatinib mesylate. The author has an hindex of 45, co-authored 126 publications receiving 15621 citations. Previous affiliations of Annick D. Van den Abbeele include Brigham and Women's Hospital & University of North Carolina at Chapel Hill.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
George D. Demetri,Margaret von Mehren,Charles D. Blanke,Annick D. Van den Abbeele,Burton L. Eisenberg,Peter J. Roberts,Michael Heinrich,David A. Tuveson,Samuel Singer,Milos J. Janicek,Jonathan A. Fletcher,Stuart G. Silverman,Sandra Silberman,Renaud Capdeville,Beate Kiese,Bin Peng,Sasa Dimitrijevic,Brian J. Druker,Christopher L. Corless,Christopher D.M. Fletcher,Heikki Joensuu +20 more
TL;DR: Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor, indicating that inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinalStromal tumors, which resist conventional chemotherapy.
Journal ArticleDOI
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Michael Heinrich,Christopher L. Corless,George D. Demetri,Charles D. Blanke,Margaret von Mehren,Heikki Joensuu,Laura McGreevey,Chang Jie Chen,Annick D. Van den Abbeele,Brian J. Druker,Beate Kiese,Burton L. Eisenberg,Peter J. Roberts,Samuel Singer,Christopher D.M. Fletcher,Sandra Silberman,Sasa Dimitrijevic,Jonathan A. Fletcher +17 more
TL;DR: Activating mutations of KIT or PDGFRA are found in the vast majority of GISTs, and the mutational status of these oncoproteins is predictive of clinical response to imatinib.
Journal ArticleDOI
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Tammy F. Chu,Tammy F. Chu,Maria Rupnick,Maria Rupnick,Risto Kerkelä,Susan M. Dallabrida,David Zurakowski,Lisa Nguyen,Kathleen C. Woulfe,Elke Pravda,Flavia Cassiola,Jayesh Desai,Suzanne George,David M. Harris,Nesreen S. Ismail,Jey-Hsin Chen,Frederick J. Schoen,Annick D. Van den Abbeele,George D. Demetri,Thomas Force,Ming-Hui Chen,Ming-Hui Chen,Jeffrey A. Morgan +22 more
TL;DR: Left ventricular dysfunction might be due, in part, to direct cardiomyocyte toxicity, exacerbated by hypertension, and patients treated with sunitinib should be closely monitored for hypertension and LVEF reduction, especially those with a history of coronary artery disease or cardiac risk factors.
Journal Article
Consensus Recommendations for the Use of 18F-FDG PET as an Indicator of Therapeutic Response in Patients in National Cancer Institute Trials
Lalitha K. Shankar,John M. Hoffman,Steve Bacharach,Michael M. Graham,Joel S. Karp,Adriaan A. Lammertsma,Steven M. Larson,David A. Mankoff,Barry A. Siegel,Annick D. Van den Abbeele,Jeffrey T. Yap,Daniel C. Sullivan +11 more
TL;DR: This paper presents a meta-modelling study of the response of positron emission tomography (PET) to radiolysis (radiolysis) and its applications to nuclear medicine and Radiology.
Journal ArticleDOI
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.
George D. Demetri,Robert S. Benjamin,Charles D. Blanke,Jean-Yves Blay,Paolo G. Casali,Haesun Choi,Christopher L. Corless,Maria Debiec-Rychter,Ronald P. DeMatteo,David S. Ettinger,George A. Fisher,Christopher D.M. Fletcher,Alessandro Gronchi,Peter Hohenberger,Miranda Hughes,Heikki Joensuu,Ian Judson,Axel Le Cesne,Robert G. Maki,Michael A. Morse,Alberto S. Pappo,Peter W.T. Pisters,Chandrajit P. Raut,Peter Reichardt,Douglas S. Tyler,Annick D. Van den Abbeele,Margaret von Mehren,Jeffrey D. Wayne,John Zalcberg +28 more
TL;DR: The GIST Task Force met for the first time in October 2003 and again in December 2006 with the purpose of expanding on the existing NCCN guidelines for gastrointestinal sarcomas and identifying areas of future research to optimize the understanding and treatment of GIST.